Dermatovenereology Department, Second Faculty of Medicine, Charles University, University Hospital Bulovka, Prague, Czech Republic.
Dermatovenereology Department, Third Faculty of Medicine, Charles University, Kralovske Vinohrady University Hospital, Prague, Czech Republic.
Dermatol Ther. 2022 Oct;35(10):e15735. doi: 10.1111/dth.15735. Epub 2022 Aug 8.
Current knowledge about human papillomavirus (HPV) infection in psoriasis patients treated with biologics is limited. In this study we evaluated the prevalence of oral and genital HPV infection in psoriasis patients treated with biologics or topical therapy for at least 6 months. The presence of HPV DNA in oral rinse and genital smears was evaluated. In total, 267 patients who met the inclusion criteria and agreed to participate were enrolled: 110 (41.2%) on topical therapy, 84 (31.5%) on anti-TNF-alpha therapy, 31 (11.6%) on anti-IL-12/23 therapy and 42 (15.7%) on anti-IL-17 therapy. The presence of genital HPV infection was detected in 34.6% of men receiving anti-TNF-α treatment, in 25.0% of patients on anti-IL-12/23 and 18.8% of patients on anti-IL-17 therapy. The difference in prevalence was not statistically different from men on topical treatment (26.3%). Prevalence of oral HPV infection was higher across all of the biologic groups (11.9% for anti-TNF-α, 12.9% for anti-IL-12/23 and 19.0% for anti-IL-17) compared to patients on topical therapy (7.3%), but statistically significant only for anti-IL-17 (p < 0.05). The presence of oral HPV infection in patients treated with biologics was significantly higher (44.0%) in patients on long-term biologic treatment (>8 years) compared to patients taking biologics for a shorter period (9.1%; p < 0.01). Our results suggest that patients on biologics for psoriasis have a higher prevalence of oral HPV infection compared to patients on topical treatment. Long-term treatment with biologics seems to be associated with a higher prevalence of oral HPV infection, independent of previous conventional immunosuppressive therapy.
目前关于接受生物制剂治疗的银屑病患者人乳头瘤病毒（HPV）感染的知识有限。在这项研究中，我们评估了接受生物制剂或局部治疗至少 6 个月的银屑病患者中口腔和生殖器 HPV 感染的患病率。评估了口腔冲洗液和生殖器涂片 HPV DNA 的存在。共有 267 名符合纳入标准并同意参与的患者被纳入：110 名（41.2%）接受局部治疗，84 名（31.5%）接受抗 TNF-α 治疗，31 名（11.6%）接受抗 IL-12/23 治疗，42 名（15.7%）接受抗 IL-17 治疗。接受抗 TNF-α 治疗的男性中，生殖器 HPV 感染的存在率为 34.6%，接受抗 IL-12/23 治疗的患者为 25.0%，接受抗 IL-17 治疗的患者为 18.8%。与接受局部治疗的男性相比，差异无统计学意义（26.3%）。所有生物制剂组的口腔 HPV 感染率均较高（抗 TNF-α 为 11.9%，抗 IL-12/23 为 12.9%，抗 IL-17 为 19.0%），与接受局部治疗的患者相比（7.3%），但抗 IL-17 有统计学意义（p<0.05）。与接受生物制剂治疗时间较短的患者（9.1%；p<0.01）相比，长期接受生物制剂治疗（>8 年）的患者口腔 HPV 感染的存在率显著更高（44.0%）。我们的结果表明，与接受局部治疗的患者相比，接受生物制剂治疗的银屑病患者口腔 HPV 感染的患病率更高。长期接受生物制剂治疗似乎与口腔 HPV 感染的患病率增加有关，与之前的常规免疫抑制治疗无关。
